135 related articles for article (PubMed ID: 22039258)
1. Blood consult: treating del(5q) myelodysplastic syndromes.
Mukherjee S; Tiu RV; Sekeres MA
Blood; 2012 Jan; 119(2):342-4. PubMed ID: 22039258
[No Abstract] [Full Text] [Related]
2. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
3. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
Wang C; McGraw KL; McLemore AF; Komrokji R; Basiorka AA; Al Ali N; Lancet JE; Padron E; Kosmider O; Fontenay M; Fenaux P; List AF; Sallman DA
Haematologica; 2022 Mar; 107(3):737-739. PubMed ID: 34320786
[No Abstract] [Full Text] [Related]
4. MDS with isolated del(5q) and internuclear bridging.
Xu Z; McGowan-Jordan J
Blood; 2017 Apr; 129(16):2333. PubMed ID: 28428239
[No Abstract] [Full Text] [Related]
5. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
Talati C; Sallman D; List AF
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):629-635. PubMed ID: 30097406
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
7. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
8. Familial occurrence of myelodysplastic syndrome with del(5q).
Volpicelli P; Latagliata R; Carmosino I; Breccia M; Vozella F; Mancini M; Cannella L; Alimena G
Leuk Lymphoma; 2011 Jun; 52(6):1143-5. PubMed ID: 21599595
[No Abstract] [Full Text] [Related]
9. What lies beyond del(5q) in myelodysplastic syndrome?
Adema V; Bejar R
Haematologica; 2013 Dec; 98(12):1819-21. PubMed ID: 24323981
[No Abstract] [Full Text] [Related]
10. Myelodysplastic syndrome associated with isolated del (5q) chromosome abnormality ("5q- syndrome").
Maslak P
Blood; 2007 Dec; 110(12):3825. PubMed ID: 18062093
[No Abstract] [Full Text] [Related]
11. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
Kerdivel G; Chesnais V; Becht E; Toma A; Cagnard N; Dumont F; Rousseau A; Fenaux P; Chevret S; Chapuis N; Boeva V; Fridman WH; Fontenay M; Kosmider O
Leukemia; 2018 Feb; 32(2):558-562. PubMed ID: 28972593
[No Abstract] [Full Text] [Related]
12. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
14. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
[TBL] [Abstract][Full Text] [Related]
15. A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia.
Kornreich L; Soulier J; Grange B; Girard S; Ouchée-Chardin M; Ceraulo A
Pediatr Blood Cancer; 2020 Jul; 67(7):e28369. PubMed ID: 32379395
[No Abstract] [Full Text] [Related]
16. Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
Steensma DP; Ebert BL
Blood; 2013 May; 121(21):4428. PubMed ID: 23704049
[No Abstract] [Full Text] [Related]
17. Two different del(5q) clones in a patient with myelodysplastic syndrome.
Braulke F; Schanz J; Steffens R; Liehr T; Manvelyan M; Chudoba I; Haase D
Leuk Lymphoma; 2011 Sep; 52(9):1811-4. PubMed ID: 21657962
[No Abstract] [Full Text] [Related]
18. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
19. Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Himmelmann A; Tchinda J
Leuk Res; 2012 May; 36(5):656-7. PubMed ID: 22177945
[No Abstract] [Full Text] [Related]
20. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
